TAAR1 as an emerging target for the treatment of psychiatric disorders

J Liu, R Wu, JX Li - Pharmacology & Therapeutics, 2023 - Elsevier
Trace amines, a group of amines expressed at the nanomolar level in the mammalian brain,
can modulate monoamine transmission. The discovery of and the functional research on the …

Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands

G Giorgioni, A Bonifazi, L Botticelli… - Medicinal Research …, 2024 - Wiley Online Library
HT1A receptor (5‐HT1A‐R) is a serotoninergic G‐protein coupled receptor subtype which
contributes to several physiological processes in both central nervous system and periphery …

TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes

S Milanović, N Dedic, R Lew, D Burton… - Diabetes, Obesity …, 2024 - Wiley Online Library
Abstract Background Metabolic syndrome (MetS), which can be induced or exacerbated by
the current class of antipsychotic drugs, is highly prevalent in patients with schizophrenia …

Structures of the amphetamine-binding receptor will aid drug discovery

HH Sitte - 2023 - nature.com
Structures of the amphetamine-binding receptor will aid drug discovery Skip to main content
Thank you for visiting nature.com. You are using a browser version with limited support for …

Large language models direct automated chemistry laboratory

AL Dias, T Rodrigues - 2023 - nature.com
Large language models direct automated chemistry laboratory Skip to main content Thank you
for visiting nature.com. You are using a browser version with limited support for CSS. To obtain …

Structure-Based Design of Novel G-Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates

Z Zhou, W Zhang, F Zhao, Y Sun, N Wang… - Journal of Medicinal …, 2024 - ACS Publications
The existing available antipsychotics have failed to manage the cognitive impairment of
schizophrenia and induced a number of seriously undesirable effects. Trace amine …

Newly identified structures of trace-amine associated receptor-1 (TAAR1) will aid discovery of next generation neuropsychiatric drugs

PC Nair, B Shajan, T Bastiampillai - Molecular Psychiatry, 2024 - nature.com
The trace-amine associated receptor-1 (TAAR1) is a member of the G-protein coupled
receptor (GPCR) receptor family and is widely distributed across the brain and …

[HTML][HTML] Trace amine associated receptor 1: predicted effects of single nucleotide variants on structure-function in geographically diverse populations

B Shajan, S Marri, T Bastiampillai, KJ Gregory… - Human Genomics, 2024 - Springer
Abstract Trace Amine Associated Receptor 1 (TAAR1) is a novel pharmaceutical target
under investigation for the treatment of several neuropsychiatric conditions. TAAR1 single …

Promising immunomodulators for management of substance and alcohol use disorders

AM Acuña, C Park, JM Leyrer-Jackson… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction The neuroimmune system has emerged as a novel target for the treatment of
substance use disorders (SUDs), with immunomodulation producing encouraging …

[HTML][HTML] Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays

E Cichero, V Francesconi, B Casini, M Casale… - Pharmaceuticals, 2023 - mdpi.com
Trace amine-associated receptor 1 (TAAR1) is an attractive target for the design of
innovative drugs to be applied in diverse pharmacological settings. Due to a non-negligible …